22 August 2019 - Novo Nordisk today announced that the European Commission has granted an extension of the indication for ...
6 August 2019 - Only biologic approved in the European Union for patients aged 12 and above with moderate-to-severe atopic dermatitis. ...
26 July 2019 - Positive opinion is based on the landmark Phase III RAINBOW trial, which showed that Lucentis (ranibizumab) is ...
28 June 2019 - EMA’s CHMP has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of ...
13 February 2019 - Eisai announced today that it has submitted an application to the EMA for its in-house discovered ...
11 February 2019 - Bristol-Myers Squibb today announced that the European Commission has approved Sprycel (dasatinib) in combination with chemotherapy ...
21 January 2019 - Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic ...
14 January 2019 - The EMA has approved Flutiform pMDI for use in the treatment of children with asthma aged ...
17 December 2018 - Bristol-Myers Squibb today announced that the CHMP of the EMA has recommended the expanded approval of ...
29 November 2018 - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic ...
19 October 2018 - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic ...
2 October 2018 - The EMA and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have published ...
21 September 2018 - Positive opinion is based on the landmark Phase III PARADIGMS trial, which showed Gilenya (fingolimod) substantially reduced ...
30 August 2018 - First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe. ...
29 August 2018 - Approval Based on Data From the Phase 1/2 '205 Study. ...